# Omega-3 and biological aging

Rating: Promising — Some human trials, or consistent animal work with a clear mechanism
Type: Compound
Updated: 2026-10-18
Canonical: https://heretic.bio/articles/omega-3-and-biological-aging.html

> Omega-3 fatty acids have one of the better randomized datasets for biological aging. In DO-HEALTH, adults 70 and over taking omega-3 for three years had modestly slower aging on several DNA methylation clocks, roughly three months, with additive effects on one clock when combined with vitamin D and exercise. The analysis was post hoc. But the same trial found no benefit on blood pressure, physical performance or cognition, and large cardiovascular trials such as VITAL were largely null, while high doses raise the risk of atrial fibrillation.

Marine omega-3 fatty acids (EPA and DHA, from fish oil or algae) are among the most-taken supplements in the world and among the most argued about. Large outcome trials have mostly been disappointing for heart attacks and cancer in the general population. But in 2025 a three-year randomized trial in older Europeans gave omega-3 a different kind of result: it modestly slowed several next-generation epigenetic aging clocks. This entry collects the omega-3 evidence that Heretic otherwise has scattered across a dozen pages, with the clock result in context.

## DO-HEALTH: the clock result

DO-HEALTH randomized 2,157 healthy European adults aged 70 and over to vitamin D, omega-3, a simple home strength programme, all combinations, or placebo, for three years (trial amounts are listed under What studies and practitioners report). A post hoc analysis of 777 participants with blood samples measured four DNA-methylation clocks (PhenoAge, GrimAge, GrimAge2 and DunedinPACE):

  * Omega-3 alone slowed PhenoAge, GrimAge2 and DunedinPACE.
  * All three interventions had additive benefits on PhenoAge.
  * Standardized effects were 0.16 to 0.32 units, about 2.9 to 3.8 months less biological ageing over three years (PMID [39900648](https://pubmed.ncbi.nlm.nih.gov/39900648/)).



Three caveats keep this from being a headline: it is a post hoc analysis, not the trial's pre-registered outcome; the effect is small; and epigenetic clocks are surrogate measures whose changes have not yet been shown to translate into longer or healthier lives (see [Biological age clocks](biological-age-clocks-measurement-and-interpretation.html)). One clock author is a founder of a foundation that licenses clock patents, a disclosed interest.

## What the same trial found on clinical outcomes

DO-HEALTH's main results, published in 2020, were null: omega-3 did not significantly improve blood pressure, physical performance, cognitive scores, non-vertebral fractures or infections at three years, though infection rates leaned lower (rate ratio 0.89, 99% CI 0.78 to 1.01) (PMID [33170239](https://pubmed.ncbi.nlm.nih.gov/33170239/)). So the clocks moved while the pre-specified clinical endpoints did not. That pattern is common in ageing research and is exactly why clock results should be read as a signal, not proof.

## The wider trial record

Trial| Population| Result  
---|---|---  
VITAL, _NEJM_ 2019| 25,871 US adults, 5.3 years| No significant reduction in major cardiovascular events (HR 0.92, 95% CI 0.80 to 1.06) or invasive cancer (HR 1.03); total myocardial infarction was lower (HR 0.72, 95% CI 0.59 to 0.90), a secondary endpoint (PMID [30415637](https://pubmed.ncbi.nlm.nih.gov/30415637/))  
DO-HEALTH, _JAMA_ 2020| 2,157 Europeans 70+, 3 years| No significant effect on six clinical endpoints (PMID [33170239](https://pubmed.ncbi.nlm.nih.gov/33170239/))  
DO-HEALTH clocks, _Nature Aging_ 2025| 777 participants, post hoc| About 3 months less epigenetic ageing over 3 years (PMID [39900648](https://pubmed.ncbi.nlm.nih.gov/39900648/))  
  
## Safety: the atrial fibrillation signal

A 2021 meta-analysis of seven cardiovascular outcome trials (81,210 people) found that omega-3 supplements raised the risk of atrial fibrillation by about 25% (HR 1.25, 95% CI 1.07 to 1.46). The risk grew with dose: HR 1.12 in trials using 1 g a day or less and 1.49 in trials using more (PMID [34612056](https://pubmed.ncbi.nlm.nih.gov/34612056/)). This matters for anyone taking high-dose fish oil on the assumption that more is better.

## Where it sits on the Heretic scale

**Promising** for the narrow claim that omega-3 slows epigenetic ageing markers: one well-run randomized trial, small effect, post hoc. It is not evidence that fish oil extends life, and the general-population outcome trials for heart disease and cancer are largely null. What would move it: a pre-registered clock endpoint replicated in a second trial, or clinical outcomes that track the clock change. Related: [Daily multivitamin (COSMOS)](daily-multivitamin-cosmos-trial.html), the other cheap supplement with a 2025-26 clock result; [Vitamin D optimization](vitamin-d-optimization.html); and [Seed oils and inflammation](seed-oils-and-inflammation.html) for the omega-6 side of the ledger.

## Sources

1. Bischoff-Ferrari HA, et al. (2025). "Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial." Nat Aging 5(3):376-385. PMID 39900648 . DOI 10.1038/s43587-024-00793-y (PubMed 39900648, DOI 10.1038/s43587-024-00793-y)
2. Bischoff-Ferrari HA, et al. (2020). "Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults: The DO-HEALTH Randomized Clinical Trial." JAMA . PMID 33170239 . DOI 10.1001/jama.2020.16909 (PubMed 33170239, DOI 10.1001/jama.2020.16909)
3. Manson JE, et al. (2019). "Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer." N Engl J Med . PMID 30415637 . DOI 10.1056/NEJMoa1811403 (PubMed 30415637, DOI 10.1056/NEJMoa1811403)
4. Gencer B, et al. (2021). "Effect of Long-Term Marine Omega-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis." Circulation . PMID 34612056 . DOI 10.1161/CIRCULATIONAHA.121.055654 (PubMed 34612056, DOI 10.1161/CIRCULATIONAHA.121.055654)